References

1. American Cancer Society. How immunotherapy is used to treat cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html. Accessed on September 2, 2020.
2. Anassi E, Ndefo UA. 2011;36(4):197-202.
3. Cancer Research Institute. New report charts dramatic growth in the global clinical trial landscape for PD-1/L1 immune checkpoint inhibitors. https://www.cancerresearch.org/news/2018/pd-1-l1-checkpoint-inhibitor-landscape-analysis. Accessed on September 2, 2020.
4. Cancer Research Institute. PD-1/PD-L1 Landscape. https://www.cancerresearch.org/scientists/immuno-oncology-landscape/pd-1-pd-l1-landscape. Accessed on September 2, 2020.
5. Chaudhari PB.. Indian J Med Paediatr Oncol. 2017;doi:10.4103/ijmpo.ijmpo_193_16.
6. Chemocare. Pembrolizumab. http://chemocare.com/chemotherapy/drug-info/Pembrolizumab.aspx. Accessed on September 2, 2020.
7. Conry RM, et al. Hum Vaccin Immunother. 2018;doi:10.1080/21645515.2017.1412896.
8. Diagnostics PT. Proleukin (Aldesleukin). https://www.proleukin.com/. Accessed on September 2, 2020.
9. FDA approves second CAR T-cell therapy. Cancer Discov. 2018;doi:10.1158/2159-8290.CD-NB2017-155.
10. Finkelmeier F, et al. Expert Rev Anti-cancer Ther. 2018;doi:10.1080/14737140.2018.1535315.
11. Jeal W, Goa KL. BioDrugs. 1997;doi:10.2165/00063030-199707040-00005.
12. Marshall HT, Djamgoz MBA. Front Oncol. 2018;doi:10.3389/fonc.2018.00315.
13. MDAnderson. Immunotherapy. https://www.mdanderson.org/treatment-options/immunotherapy.html. Accessed on September 2, 2020.
14. MDAnderson. Pioneering endogenous T-cell therapy for cancer treatments. https://oncology.medicinematters.com/immunotherapy/renal-cell-carcinoma/combination-immunotherapy-in-cancer/12038738. Accessed on September 2, 2020.
15. Melanoma Research Alliance. Immunotherapy https://www.curemelanoma.org/patient-eng/melanoma-treatment/immunotherapy/. Accessed on September 2, 2020.
16. Morrissey KM, et al. Clin Transl Sci. 2016;doi:10.1111/cts.12391.
17. Noble S, Goa KL. BioDrugs. 1997;doi:10.2165/00063030-199707050-00007.
18. Resources BMS. OpDivo (Nivolumab). https://www.opdivo.com/. Accessed on September 2, 2020.
19. Sambi M, et al. J Oncol. 2019;doi:10.1155/2019/4508794.
20. Sarshekeh AM, et al. Future Oncol. 2018;doi:10.2217/fon-2017-0696.
21. Schmidt C. Nature. 2017;doi:10.1038/d41586-017-08702-7.
22. Smith KM, Desai J. Expert Rev Anti-cancer Ther. 2018;doi:10.1080/14737140.2018.1480942.
23. ThermoFisher Scientific. Immuno-Oncology Research. https://www.thermofisher.com/us/en/home/life-science/cancer-research/immuno-oncology-research.html?icid=BID_Div_LITLblog_IOpost1_20180615. Accessed on September 2, 2020.

Thank you for participating in this module. Click below to download the certificate.